Earned Wealth Advisors LLC Purchases Shares of 7,859 Johnson & Johnson (NYSE:JNJ)

Key Points

• Earned Wealth Advisors LLC purchased 7,859 shares of Johnson & Johnson valued at approximately $1.3 million, increasing its stake in the company.
• Johnson & Johnson reported earnings of $2.77 per share, exceeding analyst expectations, with revenue of $23.74 billion for the most recent quarter.
• The company's most recent quarterly dividend is set at $1.30 per share, with an annualized payout of $5.20, reflecting a 3.1% dividend yield.

Earned Wealth Advisors LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 7,859 shares of the company's stock, valued at approximately $1,303,000.

Several other institutional investors have also recently added to or reduced their stakes in JNJ. Bernard Wealth Management Corp. bought a new position in Johnson & Johnson in the fourth quarter worth approximately $36,000. Highline Wealth Partners LLC boosted its holdings in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares in the last quarter. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson in the first quarter valued at approximately $49,000. Capital A Wealth Management LLC bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $50,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson in the first quarter valued at approximately $52,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $167.33 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock has a fifty day moving average of $157.46 and a 200-day moving average of $156.68. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The stock has a market cap of $402.99 billion, a PE ratio of 17.90, a price-to-earnings-growth ratio of 2.13 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the company posted $2.82 earnings per share. The company's revenue was up 5.8% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on JNJ shares. Barclays raised their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their target price for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Finally, UBS Group raised their target price on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.